Seqirus Produces Cell-Based Influenza Vaccines at Commercial Scale
The company successfully produced cell-based influenza vaccines at a commercial scale in its facility in NC.
On June 21, 2017, Seqirus announced that it has successfully produced cell-based influenza vaccines at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs. The company produced the vaccines at its manufacturing facility in Holly Springs, NC.
CVVs are prepared by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) and associated laboratories and are used by manufacturers to develop and produce influenza vaccines. In 2016, WHO began to recommend cell-derived CVVs and FDA issued an approval for Seqirus to use them in the production of cell-based influenza vaccines at Holly Springs.
This year, Seqirus was successful in using a cell-derived H3N2 CVV in the production of its cell-based seasonal influenza vaccine, making the end-to-end production of this strain exclusively cell-based. The company plans to utilize cell-derived CVV technology for the production of other vaccine strains produced at the Holly Springs site in the future.
Source: Seqirus
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
